Literature DB >> 16816558

Predictive value of absolute CD4 cell count for disease progression in untreated HIV-1-infected children.

.   

Abstract

OBJECTIVES: To describe the relationship between absolute CD4 cell count and the short-term risk of disease progression in HIV-1-infected children.
DESIGN: A meta-analysis of individual longitudinal data on HIV-1-infected children enrolled in trials and cohort studies in Europe and the USA.
METHODS: The risks of progression to death and AIDS (or death) within 12 months, in terms of age and the most recent CD4 cell count, were estimated using parametric survival models. The analysis was restricted to measurements before the start of antiretroviral therapy except zidovudine monotherapy. The values of the absolute CD4 cell count and percentage predicting selected levels of disease progression risk were determined from this and previous models.
RESULTS: A total of 566 deaths was observed over 9128 person-years of follow-up, and 992 children progressed to AIDS or death over 7309 person-years of follow-up. In children older than 4 or 5 years, the estimated risk of disease progression increased sharply when the CD4 cell count fell below 200-300 cells/microl. As with other immunological markers, CD4 cell count was less prognostic in younger children. The CD4 cell count values predicting a 12-month risk of death of 2-5% and of AIDS of 5-10% were much more strongly influenced by age than equivalent CD4 cell percentage values.
CONCLUSION: This study suggests it may be appropriate to extend CD4 cell count criteria for initiating antiretroviral therapy in HIV-1-infected adults to children as young as 4 or 5 years. Monitoring by CD4 cell count in younger children is problematical because age is a highly influential variable.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16816558     DOI: 10.1097/01.aids.0000232237.20792.68

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  30 in total

1.  Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life.

Authors:  A Bamford; A Turkova; H Lyall; C Foster; N Klein; D Bastiaans; D Burger; S Bernadi; K Butler; E Chiappini; P Clayden; M Della Negra; V Giacomet; C Giaquinto; D Gibb; L Galli; M Hainaut; M Koros; L Marques; E Nastouli; T Niehues; A Noguera-Julian; P Rojo; C Rudin; H J Scherpbier; G Tudor-Williams; S B Welch
Journal:  HIV Med       Date:  2015-02-03       Impact factor: 3.180

Review 2.  Pharmacokinetic optimization of antiretroviral therapy in children and adolescents.

Authors:  Michael N Neely; Natella Y Rakhmanina
Journal:  Clin Pharmacokinet       Date:  2011-03       Impact factor: 6.447

3.  Predictors of loss to follow-up after engagement in care of HIV-infected children ineligible for antiretroviral therapy in an HIV cohort study in India.

Authors:  Gerardo Alvarez-Uria; Praveen Kumar Naik; Manoranjan Midde; Raghavakalyan Pakam
Journal:  Germs       Date:  2014-03-03

Review 4.  The Diagnosis of HIV Infection in Infants and Children.

Authors:  Alireza Abdollahi; Hana Saffar
Journal:  Iran J Pathol       Date:  2016

5.  Antiretroviral treatment of US children with perinatally acquired HIV infection: temporal changes in therapy between 1991 and 2009 and predictors of immunologic and virologic outcomes.

Authors:  Russell B Van Dyke; Kunjal Patel; George K Siberry; Sandra K Burchett; Stephen A Spector; Miriam C Chernoff; Jennifer S Read; Lynne M Mofenson; George R Seage
Journal:  J Acquir Immune Defic Syndr       Date:  2011-06-01       Impact factor: 3.731

Review 6.  Current and future antiretroviral treatment options in paediatric HIV infection.

Authors:  Carlo Giaquinto; Erika Morelli; Federica Fregonese; Osvalda Rampon; Martina Penazzato; Anita de Rossi; Ruggero D'Elia
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

7.  Absolute CD4+ T-lymphocyte count as a surrogate marker of pediatric human immunodeficiency virus disease progression.

Authors:  Elijah Paintsil; Musie Ghebremichael; Sostena Romano; Warren A Andiman
Journal:  Pediatr Infect Dis J       Date:  2008-07       Impact factor: 2.129

8.  Replicative capacity of human immunodeficiency virus type 1 transmitted from mother to child is associated with pediatric disease progression rate.

Authors:  Julia G Prado; Andrew Prendergast; Christina Thobakgale; Claudia Molina; Gareth Tudor-Williams; Thumbi Ndung'u; Bruce D Walker; Philip Goulder
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

9.  Pharmacotherapy of pediatric and adolescent HIV infection.

Authors:  Susan J Schuval
Journal:  Ther Clin Risk Manag       Date:  2009-06-22       Impact factor: 2.423

10.  Lymphocyte subsets in healthy Malawians: implications for immunologic assessment of HIV infection in Africa.

Authors:  Wilson L Mandala; Jenny M MacLennan; Esther N Gondwe; Steven A Ward; Malcolm E Molyneux; Calman A MacLennan
Journal:  J Allergy Clin Immunol       Date:  2009-11-26       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.